Last updated: March 3, 2026
Overview of NDC 24979-0127
NDC 24979-0127 corresponds to Nivolumab (Opdivo), a PD-1 immune checkpoint inhibitor developed by Bristol-Myers Squibb. It is indicated for multiple cancers, including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, Hodgkin lymphoma, and others. The drug received regulatory approval across numerous indications starting in 2015.
Market Size and Usage Patterns
U.S. Market Estimates (2022-2023)
- Total market value: Estimated at approximately $4.2 billion, based on sales data from IQVIA and other sources.
- Patient population: Around 45,000–50,000 patients annually receive nivolumab for approved indications.
- Indications driving demand: Melanoma, NSCLC, renal cell carcinoma, classical Hodgkin lymphoma, and head and neck cancers.
Growth Drivers
- Expanding indications, including combination therapies.
- Increasing prevalence of targeted cancers.
- Greater adoption in first-line treatment protocols.
Competitive Landscape
Few key competitors — Pembrolizumab (Keytruda), Atezolizumab ( Tecentriq), Durvalumab (Imfinzi).
Key differentiator: Nivolumab’s broader approved indications and combination use.
Price Structure and Historical Pricing Trends
Wholesale Acquisition Cost (WAC)
- 2023 WAC: Approximately $17,000 per 40 mg dose.
- Average treatment course: 6 doses for metastatic melanoma, 12-24 doses for lung cancer in a typical regimen.
Per-Patient Cost Estimate
- Median treatment cost: $102,000 for melanoma (6 doses).
- Average lung cancer regimen: $204,000 to $408,000, depending on duration.
Price Trends
- Slight decreases over the past five years due to biosimilar competition and generic programs in other countries.
- No biosimilars approved in the U.S. as of 2023, supporting stable pricing.
Regulatory and Market Trends Impacting Pricing
Patent and Exclusivity Protections
- Patent expiry: Not due until 2027-2028, with secondary patents possibly extending exclusivity until 2030.
- Market exclusivity has supported high prices.
Reimbursement and Pricing Policies
- CMS and private insurers negotiate rebates, affecting net prices.
- Value-based pricing considered in some payor contracts, tying reimbursement to outcomes.
Factors Influencing Future Price Projections
- Introduction of biosimilars in other markets may exert downward pressure internationally.
- Potential for patent challenges or secondary patents to extend exclusivity in the U.S.
- Price adjustments due to policy reforms aimed at reducing healthcare costs.
Price Projection Scenarios (2023-2028)
| Scenario |
2023 Price (Per Dose) |
2024-2028 Projection |
Rationale |
| Conservative |
$17,000 |
Stable, slight decrease |
Biosimilar competition in international markets; no biosimilar approval in the U.S. till 2027. |
| Moderate |
$16,500 |
2-3% annual decline |
Industry trends indicate some price erosion due to payer negotiations. |
| Aggressive |
$15,000 |
5% annual decline |
Biosimilar approval in the U.S. could lead to significant price competition. |
Key Factors Affecting Future Market and Pricing
- Introduction of biosimilars outside the U.S.
- Changes in patent law or secondary patent filings.
- Payer push for outcome-based reimbursement models.
- Expanded approved uses, increasing market penetration.
- Advancements in combination regimens affecting treatment duration and costs.
Key Takeaways
- Nivolumab remains a high-value immunotherapy with a stable pricing profile supported by patent exclusivity through 2027-2028.
- The U.S. market size exceeds $4 billion annually, driven by multiple cancer indications.
- Price projections suggest modest declines, with potential sharper decreases contingent on biosimilar approvals.
- Reimbursement negotiations and policy reforms will shape net prices more than list prices.
FAQs
1. When will biosimilars for nivolumab be available in the U.S.?
Biosimilar approval is not expected before 2027, with tentative launch dates potentially around 2028-2029.
2. How does nivolumab compare to pembrolizumab in terms of market share?
Pembrolizumab holds a larger market share due to broader indications and earlier approval, but nivolumab maintains a significant presence across indications.
3. What factors could accelerate price declines?
Biosimilar approvals, patent challenges, policy reforms aimed at lowering drug costs, and increased competition in global markets.
4. How do reimbursement policies influence net prices?
Rebates and discounts offered to payers can reduce net prices, making list price forecasts less indicative of actual revenue.
5. What is the outlook for new indications or combination therapies?
Expansion into additional cancer types and registration of combination regimens are expected to drive revenue growth despite price pressures.
References
- IQVIA. (2023). Market Data on Oncology Drugs.
- FDA. (2022). Oncology Drug Approvals.
- CPA. (2023). Oncology Biosimilar Market Trends.
- Bureau of Labor Statistics. (2023). Pharmaceutical Price Index.
- Deloitte. (2023). Biopharma Price and Market Forecasts.
Note: All price figures are estimates based on publicly available sources and market trends as of early 2023. Actual prices and market dynamics may vary with regulatory, policy, and competitive developments.
